TCR-T (T Cell Receptor-Engineered T cell) immunotherapy is a type of adoptive cellular immunotherapy, which harnesses the power of a patient's own immune system to fight cancer. It is an advanced and personalized approach in cancer treatment that involves genetic modification of a patient's T cells, a type of white blood cell that plays a crucial role in immune response.
The global TCR-T Cellular Immunotherapy market was valued at US$ million in 2023 and is anticipated to reach US$ million by 2030, witnessing a CAGR of %during the forecast period 2024-2030.
North American market for TCR-T Cellular Immunotherapy is estimated to increase from $ million in 2023 to reach $ million by 2030, at a CAGR of % during the forecast period of 2024 through 2030.
Asia-Pacific market for TCR-T Cellular Immunotherapy is estimated to increase from $ million in 2023 to reach $ million by 2030, at a CAGR of % during the forecast period of 2024 through 2030.
The global market for TCR-T Cellular Immunotherapy in Cervical Cancer is estimated to increase from $ million in 2023 to $ million by 2030, at a CAGR of % during the forecast period of 2024 through 2030.
The major global companies of TCR-T Cellular Immunotherapy include BioNTech, Adaptimmune, Immunocore, Medigene AG, bluebird bio, TCR2 Therapeutics, Immatics, TScan Therapeutics, 3T Biosciences, Adaptive Biotechnologies, etc. In 2023, the world's top three vendors accounted for approximately % of the revenue.
This report aims to provide a comprehensive presentation of the global market for TCR-T Cellular Immunotherapy, with both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding TCR-T Cellular Immunotherapy.
The TCR-T Cellular Immunotherapy market size, estimations, and forecasts are provided in terms of and revenue ($ millions), considering 2023 as the base year, with history and forecast data for the period from 2019 to 2030. This report segments the global TCR-T Cellular Immunotherapy market comprehensively. Regional market sizes, concerning products by Type, by Application, and by players, are also provided.
For a more in-depth understanding of the market, the report provides profiles of the competitive landscape, key competitors, and their respective market ranks. The report also discusses technological trends and new product developments.
The report will help the TCR-T Cellular Immunotherapy companies, new entrants, and industry chain related companies in this market with information on the revenues for the overall market and the sub-segments across the different segments, by company, by Type, by Application, and by regions.
麻豆原创 Segmentation
By Company
BioNTech
Adaptimmune
Immunocore
Medigene AG
bluebird bio
TCR2 Therapeutics
Immatics
TScan Therapeutics
3T Biosciences
Adaptive Biotechnologies
Kite Pharma
RootPath
Eureka Therapeutics
Lion TCR
Guangzhou Xiangxue Pharmaceutical
Fosun Kite Biotechnology
Shanghai JW Therapeutics
Shanghai Heng Rui Yuan Zheng Biotechnology
Shenzhen Innovation Immunotechnology
Suzhou Neowise Biotechnology
Shenzhen BinDeBio Technology
Beijing CorreGene Biotechnology
TCRCure Biopharma Technology
BriSTAR Immunotech
Shanghai iCell Biotechnology
Segment by Type
Autologous
Allogeneic
Segment by Application
Cervical Cancer
Colorectal Cancer
Esophageal Cancer
Pancreatic Cancer
Lung Cancer
By Region
North America
United States
Canada
Asia-Pacific
China
Japan
South Korea
Southeast Asia
India
Australia
Rest of Asia
Europe
Germany
France
U.K.
Italy
Russia
Nordic Countries
Rest of Europe
Latin America
Mexico
Brazil
Rest of Latin America
Middle East & Africa
Turkey
Saudi Arabia
UAE
Rest of MEA
Chapter Outline
Chapter 1: Introduces the report scope of the report, executive summary of different market segments (by Type, by Application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 2: Introduces executive summary of global market size, regional market size, this section also introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by companies in the industry, and the analysis of relevant policies in the industry.
Chapter 3: Detailed analysis of TCR-T Cellular Immunotherapy company competitive landscape, revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 4: Provides the analysis of various market segments by Type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by Application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6, 7, 8, 9, 10: North America, Europe, Asia Pacific, Latin America, Middle East and Africa segment by country. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and capacity of each country in the world.
Chapter 11: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
Chapter 12: The main points and conclusions of the report.
Please Note - This is an on demand report and will be delivered in 2 business days (48 hours) post payment.
1 Report Overview
1.1 Study Scope
1.2 麻豆原创 Analysis by Type
1.2.1 Global TCR-T Cellular Immunotherapy 麻豆原创 Size Growth Rate by Type: 2019 VS 2023 VS 2030
1.2.2 Autologous
1.2.3 Allogeneic
1.3 麻豆原创 by Application
1.3.1 Global TCR-T Cellular Immunotherapy 麻豆原创 Growth by Application: 2019 VS 2023 VS 2030
1.3.2 Cervical Cancer
1.3.3 Colorectal Cancer
1.3.4 Esophageal Cancer
1.3.5 Pancreatic Cancer
1.3.6 Lung Cancer
1.4 Assumptions and Limitations
1.5 Study Objectives
1.6 Years Considered
2 Global Growth Trends
2.1 Global TCR-T Cellular Immunotherapy 麻豆原创 Perspective (2019-2030)
2.2 Global TCR-T Cellular Immunotherapy Growth Trends by Region
2.2.1 Global TCR-T Cellular Immunotherapy 麻豆原创 Size by Region: 2019 VS 2023 VS 2030
2.2.2 TCR-T Cellular Immunotherapy Historic 麻豆原创 Size by Region (2019-2024)
2.2.3 TCR-T Cellular Immunotherapy Forecasted 麻豆原创 Size by Region (2025-2030)
2.3 TCR-T Cellular Immunotherapy 麻豆原创 Dynamics
2.3.1 TCR-T Cellular Immunotherapy Industry Trends
2.3.2 TCR-T Cellular Immunotherapy 麻豆原创 Drivers
2.3.3 TCR-T Cellular Immunotherapy 麻豆原创 Challenges
2.3.4 TCR-T Cellular Immunotherapy 麻豆原创 Restraints
3 Competition Landscape by Key Players
3.1 Global Top TCR-T Cellular Immunotherapy Players by Revenue
3.1.1 Global Top TCR-T Cellular Immunotherapy Players by Revenue (2019-2024)
3.1.2 Global TCR-T Cellular Immunotherapy Revenue 麻豆原创 Share by Players (2019-2024)
3.2 Global TCR-T Cellular Immunotherapy 麻豆原创 Share by Company Type (Tier 1, Tier 2, and Tier 3)
3.3 Global Key Players Ranking by TCR-T Cellular Immunotherapy Revenue
3.4 Global TCR-T Cellular Immunotherapy 麻豆原创 Concentration Ratio
3.4.1 Global TCR-T Cellular Immunotherapy 麻豆原创 Concentration Ratio (CR5 and HHI)
3.4.2 Global Top 10 and Top 5 Companies by TCR-T Cellular Immunotherapy Revenue in 2023
3.5 Global Key Players of TCR-T Cellular Immunotherapy Head office and Area Served
3.6 Global Key Players of TCR-T Cellular Immunotherapy, Product and Application
3.7 Global Key Players of TCR-T Cellular Immunotherapy, Date of Enter into This Industry
3.8 Mergers & Acquisitions, Expansion Plans
4 TCR-T Cellular Immunotherapy Breakdown Data by Type
4.1 Global TCR-T Cellular Immunotherapy Historic 麻豆原创 Size by Type (2019-2024)
4.2 Global TCR-T Cellular Immunotherapy Forecasted 麻豆原创 Size by Type (2025-2030)
5 TCR-T Cellular Immunotherapy Breakdown Data by Application
5.1 Global TCR-T Cellular Immunotherapy Historic 麻豆原创 Size by Application (2019-2024)
5.2 Global TCR-T Cellular Immunotherapy Forecasted 麻豆原创 Size by Application (2025-2030)
6 North America
6.1 North America TCR-T Cellular Immunotherapy 麻豆原创 Size (2019-2030)
6.2 North America TCR-T Cellular Immunotherapy 麻豆原创 Growth Rate by Country: 2019 VS 2023 VS 2030
6.3 North America TCR-T Cellular Immunotherapy 麻豆原创 Size by Country (2019-2024)
6.4 North America TCR-T Cellular Immunotherapy 麻豆原创 Size by Country (2025-2030)
6.5 United States
6.6 Canada
7 Europe
7.1 Europe TCR-T Cellular Immunotherapy 麻豆原创 Size (2019-2030)
7.2 Europe TCR-T Cellular Immunotherapy 麻豆原创 Growth Rate by Country: 2019 VS 2023 VS 2030
7.3 Europe TCR-T Cellular Immunotherapy 麻豆原创 Size by Country (2019-2024)
7.4 Europe TCR-T Cellular Immunotherapy 麻豆原创 Size by Country (2025-2030)
7.5 Germany
7.6 France
7.7 U.K.
7.8 Italy
7.9 Russia
7.10 Nordic Countries
8 Asia-Pacific
8.1 Asia-Pacific TCR-T Cellular Immunotherapy 麻豆原创 Size (2019-2030)
8.2 Asia-Pacific TCR-T Cellular Immunotherapy 麻豆原创 Growth Rate by Country: 2019 VS 2023 VS 2030
8.3 Asia-Pacific TCR-T Cellular Immunotherapy 麻豆原创 Size by Region (2019-2024)
8.4 Asia-Pacific TCR-T Cellular Immunotherapy 麻豆原创 Size by Region (2025-2030)
8.5 China
8.6 Japan
8.7 South Korea
8.8 Southeast Asia
8.9 India
8.10 Australia
9 Latin America
9.1 Latin America TCR-T Cellular Immunotherapy 麻豆原创 Size (2019-2030)
9.2 Latin America TCR-T Cellular Immunotherapy 麻豆原创 Growth Rate by Country: 2019 VS 2023 VS 2030
9.3 Latin America TCR-T Cellular Immunotherapy 麻豆原创 Size by Country (2019-2024)
9.4 Latin America TCR-T Cellular Immunotherapy 麻豆原创 Size by Country (2025-2030)
9.5 Mexico
9.6 Brazil
10 Middle East & Africa
10.1 Middle East & Africa TCR-T Cellular Immunotherapy 麻豆原创 Size (2019-2030)
10.2 Middle East & Africa TCR-T Cellular Immunotherapy 麻豆原创 Growth Rate by Country: 2019 VS 2023 VS 2030
10.3 Middle East & Africa TCR-T Cellular Immunotherapy 麻豆原创 Size by Country (2019-2024)
10.4 Middle East & Africa TCR-T Cellular Immunotherapy 麻豆原创 Size by Country (2025-2030)
10.5 Turkey
10.6 Saudi Arabia
10.7 UAE
11 Key Players Profiles
11.1 BioNTech
11.1.1 BioNTech Company Details
11.1.2 BioNTech Business Overview
11.1.3 BioNTech TCR-T Cellular Immunotherapy Introduction
11.1.4 BioNTech Revenue in TCR-T Cellular Immunotherapy Business (2019-2024)
11.1.5 BioNTech Recent Development
11.2 Adaptimmune
11.2.1 Adaptimmune Company Details
11.2.2 Adaptimmune Business Overview
11.2.3 Adaptimmune TCR-T Cellular Immunotherapy Introduction
11.2.4 Adaptimmune Revenue in TCR-T Cellular Immunotherapy Business (2019-2024)
11.2.5 Adaptimmune Recent Development
11.3 Immunocore
11.3.1 Immunocore Company Details
11.3.2 Immunocore Business Overview
11.3.3 Immunocore TCR-T Cellular Immunotherapy Introduction
11.3.4 Immunocore Revenue in TCR-T Cellular Immunotherapy Business (2019-2024)
11.3.5 Immunocore Recent Development
11.4 Medigene AG
11.4.1 Medigene AG Company Details
11.4.2 Medigene AG Business Overview
11.4.3 Medigene AG TCR-T Cellular Immunotherapy Introduction
11.4.4 Medigene AG Revenue in TCR-T Cellular Immunotherapy Business (2019-2024)
11.4.5 Medigene AG Recent Development
11.5 bluebird bio
11.5.1 bluebird bio Company Details
11.5.2 bluebird bio Business Overview
11.5.3 bluebird bio TCR-T Cellular Immunotherapy Introduction
11.5.4 bluebird bio Revenue in TCR-T Cellular Immunotherapy Business (2019-2024)
11.5.5 bluebird bio Recent Development
11.6 TCR2 Therapeutics
11.6.1 TCR2 Therapeutics Company Details
11.6.2 TCR2 Therapeutics Business Overview
11.6.3 TCR2 Therapeutics TCR-T Cellular Immunotherapy Introduction
11.6.4 TCR2 Therapeutics Revenue in TCR-T Cellular Immunotherapy Business (2019-2024)
11.6.5 TCR2 Therapeutics Recent Development
11.7 Immatics
11.7.1 Immatics Company Details
11.7.2 Immatics Business Overview
11.7.3 Immatics TCR-T Cellular Immunotherapy Introduction
11.7.4 Immatics Revenue in TCR-T Cellular Immunotherapy Business (2019-2024)
11.7.5 Immatics Recent Development
11.8 TScan Therapeutics
11.8.1 TScan Therapeutics Company Details
11.8.2 TScan Therapeutics Business Overview
11.8.3 TScan Therapeutics TCR-T Cellular Immunotherapy Introduction
11.8.4 TScan Therapeutics Revenue in TCR-T Cellular Immunotherapy Business (2019-2024)
11.8.5 TScan Therapeutics Recent Development
11.9 3T Biosciences
11.9.1 3T Biosciences Company Details
11.9.2 3T Biosciences Business Overview
11.9.3 3T Biosciences TCR-T Cellular Immunotherapy Introduction
11.9.4 3T Biosciences Revenue in TCR-T Cellular Immunotherapy Business (2019-2024)
11.9.5 3T Biosciences Recent Development
11.10 Adaptive Biotechnologies
11.10.1 Adaptive Biotechnologies Company Details
11.10.2 Adaptive Biotechnologies Business Overview
11.10.3 Adaptive Biotechnologies TCR-T Cellular Immunotherapy Introduction
11.10.4 Adaptive Biotechnologies Revenue in TCR-T Cellular Immunotherapy Business (2019-2024)
11.10.5 Adaptive Biotechnologies Recent Development
11.11 Kite Pharma
11.11.1 Kite Pharma Company Details
11.11.2 Kite Pharma Business Overview
11.11.3 Kite Pharma TCR-T Cellular Immunotherapy Introduction
11.11.4 Kite Pharma Revenue in TCR-T Cellular Immunotherapy Business (2019-2024)
11.11.5 Kite Pharma Recent Development
11.12 RootPath
11.12.1 RootPath Company Details
11.12.2 RootPath Business Overview
11.12.3 RootPath TCR-T Cellular Immunotherapy Introduction
11.12.4 RootPath Revenue in TCR-T Cellular Immunotherapy Business (2019-2024)
11.12.5 RootPath Recent Development
11.13 Eureka Therapeutics
11.13.1 Eureka Therapeutics Company Details
11.13.2 Eureka Therapeutics Business Overview
11.13.3 Eureka Therapeutics TCR-T Cellular Immunotherapy Introduction
11.13.4 Eureka Therapeutics Revenue in TCR-T Cellular Immunotherapy Business (2019-2024)
11.13.5 Eureka Therapeutics Recent Development
11.14 Lion TCR
11.14.1 Lion TCR Company Details
11.14.2 Lion TCR Business Overview
11.14.3 Lion TCR TCR-T Cellular Immunotherapy Introduction
11.14.4 Lion TCR Revenue in TCR-T Cellular Immunotherapy Business (2019-2024)
11.14.5 Lion TCR Recent Development
11.15 Guangzhou Xiangxue Pharmaceutical
11.15.1 Guangzhou Xiangxue Pharmaceutical Company Details
11.15.2 Guangzhou Xiangxue Pharmaceutical Business Overview
11.15.3 Guangzhou Xiangxue Pharmaceutical TCR-T Cellular Immunotherapy Introduction
11.15.4 Guangzhou Xiangxue Pharmaceutical Revenue in TCR-T Cellular Immunotherapy Business (2019-2024)
11.15.5 Guangzhou Xiangxue Pharmaceutical Recent Development
11.16 Fosun Kite Biotechnology
11.16.1 Fosun Kite Biotechnology Company Details
11.16.2 Fosun Kite Biotechnology Business Overview
11.16.3 Fosun Kite Biotechnology TCR-T Cellular Immunotherapy Introduction
11.16.4 Fosun Kite Biotechnology Revenue in TCR-T Cellular Immunotherapy Business (2019-2024)
11.16.5 Fosun Kite Biotechnology Recent Development
11.17 Shanghai JW Therapeutics
11.17.1 Shanghai JW Therapeutics Company Details
11.17.2 Shanghai JW Therapeutics Business Overview
11.17.3 Shanghai JW Therapeutics TCR-T Cellular Immunotherapy Introduction
11.17.4 Shanghai JW Therapeutics Revenue in TCR-T Cellular Immunotherapy Business (2019-2024)
11.17.5 Shanghai JW Therapeutics Recent Development
11.18 Shanghai Heng Rui Yuan Zheng Biotechnology
11.18.1 Shanghai Heng Rui Yuan Zheng Biotechnology Company Details
11.18.2 Shanghai Heng Rui Yuan Zheng Biotechnology Business Overview
11.18.3 Shanghai Heng Rui Yuan Zheng Biotechnology TCR-T Cellular Immunotherapy Introduction
11.18.4 Shanghai Heng Rui Yuan Zheng Biotechnology Revenue in TCR-T Cellular Immunotherapy Business (2019-2024)
11.18.5 Shanghai Heng Rui Yuan Zheng Biotechnology Recent Development
11.19 Shenzhen Innovation Immunotechnology
11.19.1 Shenzhen Innovation Immunotechnology Company Details
11.19.2 Shenzhen Innovation Immunotechnology Business Overview
11.19.3 Shenzhen Innovation Immunotechnology TCR-T Cellular Immunotherapy Introduction
11.19.4 Shenzhen Innovation Immunotechnology Revenue in TCR-T Cellular Immunotherapy Business (2019-2024)
11.19.5 Shenzhen Innovation Immunotechnology Recent Development
11.20 Suzhou Neowise Biotechnology
11.20.1 Suzhou Neowise Biotechnology Company Details
11.20.2 Suzhou Neowise Biotechnology Business Overview
11.20.3 Suzhou Neowise Biotechnology TCR-T Cellular Immunotherapy Introduction
11.20.4 Suzhou Neowise Biotechnology Revenue in TCR-T Cellular Immunotherapy Business (2019-2024)
11.20.5 Suzhou Neowise Biotechnology Recent Development
11.21 Shenzhen BinDeBio Technology
11.21.1 Shenzhen BinDeBio Technology Company Details
11.21.2 Shenzhen BinDeBio Technology Business Overview
11.21.3 Shenzhen BinDeBio Technology TCR-T Cellular Immunotherapy Introduction
11.21.4 Shenzhen BinDeBio Technology Revenue in TCR-T Cellular Immunotherapy Business (2019-2024)
11.21.5 Shenzhen BinDeBio Technology Recent Development
11.22 Beijing CorreGene Biotechnology
11.22.1 Beijing CorreGene Biotechnology Company Details
11.22.2 Beijing CorreGene Biotechnology Business Overview
11.22.3 Beijing CorreGene Biotechnology TCR-T Cellular Immunotherapy Introduction
11.22.4 Beijing CorreGene Biotechnology Revenue in TCR-T Cellular Immunotherapy Business (2019-2024)
11.22.5 Beijing CorreGene Biotechnology Recent Development
11.23 TCRCure Biopharma Technology
11.23.1 TCRCure Biopharma Technology Company Details
11.23.2 TCRCure Biopharma Technology Business Overview
11.23.3 TCRCure Biopharma Technology TCR-T Cellular Immunotherapy Introduction
11.23.4 TCRCure Biopharma Technology Revenue in TCR-T Cellular Immunotherapy Business (2019-2024)
11.23.5 TCRCure Biopharma Technology Recent Development
11.24 BriSTAR Immunotech
11.24.1 BriSTAR Immunotech Company Details
11.24.2 BriSTAR Immunotech Business Overview
11.24.3 BriSTAR Immunotech TCR-T Cellular Immunotherapy Introduction
11.24.4 BriSTAR Immunotech Revenue in TCR-T Cellular Immunotherapy Business (2019-2024)
11.24.5 BriSTAR Immunotech Recent Development
11.25 Shanghai iCell Biotechnology
11.25.1 Shanghai iCell Biotechnology Company Details
11.25.2 Shanghai iCell Biotechnology Business Overview
11.25.3 Shanghai iCell Biotechnology TCR-T Cellular Immunotherapy Introduction
11.25.4 Shanghai iCell Biotechnology Revenue in TCR-T Cellular Immunotherapy Business (2019-2024)
11.25.5 Shanghai iCell Biotechnology Recent Development
12 Analyst's Viewpoints/Conclusions
13 Appendix
13.1 Research Methodology
13.1.1 Methodology/Research Approach
13.1.1.1 Research Programs/Design
13.1.1.2 麻豆原创 Size Estimation
13.1.1.3 麻豆原创 Breakdown and Data Triangulation
13.1.2 Data Source
13.1.2.1 Secondary Sources
13.1.2.2 Primary Sources
13.2 Author Details
13.3 Disclaimer
BioNTech
Adaptimmune
Immunocore
Medigene AG
bluebird bio
TCR2 Therapeutics
Immatics
TScan Therapeutics
3T Biosciences
Adaptive Biotechnologies
Kite Pharma
RootPath
Eureka Therapeutics
Lion TCR
Guangzhou Xiangxue Pharmaceutical
Fosun Kite Biotechnology
Shanghai JW Therapeutics
Shanghai Heng Rui Yuan Zheng Biotechnology
Shenzhen Innovation Immunotechnology
Suzhou Neowise Biotechnology
Shenzhen BinDeBio Technology
Beijing CorreGene Biotechnology
TCRCure Biopharma Technology
BriSTAR Immunotech
Shanghai iCell Biotechnology
听
听
*If Applicable.
